

COMPANY OVERVIEW

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

RECENT NEWS

[Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018](#)

Feb 22 2018, 8:30 AM EST

[Moleculin Announces Pricing of \\$9 Million Registered Direct Offering](#)

Feb 16 2018, 8:28 AM EST

[Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment](#)

Feb 15 2018, 8:30 AM EST

STOCK OVERVIEW

Symbol	MBRX
Exchange	NASDAQ
Shares OS	21,136,059
Market Cap	\$40.79M
Last Price	\$1.93
52-Week Range	\$0.7064 - \$3.75

INVESTOR RELATIONS

Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700

MANAGEMENT TEAM

Walter V. Klemp

Founder, President, Chairman, CEO, and Business Advisory Board Member

Donald Picker, PhD

Chief Scientific Officer

Robert Shepard, MD, FACP

Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD

Chief Medical Officer - New Products

Jonathan P. Foster

Chief Financial Officer

MOLECULIN BIOTECH, INC.

2575 W. Bellfort
Ste. 333
Houston, TX 77054
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.